Last reviewed · How we verify
Opioids taper off — Competitive Intelligence Brief
phase 3
Pain Management / Addiction Medicine
Small molecule
Live · refreshed every 30 min
Target snapshot
Opioids taper off (Opioids taper off) — Rigshospitalet, Denmark. A structured tapering protocol that gradually reduces opioid dosing to minimize withdrawal symptoms and dependence while managing pain.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Opioids taper off TARGET | Opioids taper off | Rigshospitalet, Denmark | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Opioids taper off CI watch — RSS
- Opioids taper off CI watch — Atom
- Opioids taper off CI watch — JSON
- Opioids taper off alone — RSS
Cite this brief
Drug Landscape (2026). Opioids taper off — Competitive Intelligence Brief. https://druglandscape.com/ci/opioids-taper-off. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing